 |
|
Treatment of Chronic Parkinson's Disease With Controlled-Release Carbidopa/Levodopa
J. Thomas Hutton, MD, PhD;
Jerry L. Morris, MA;
Gustavo C. Román, MD;
Susan C. Imke, MS;
Jeffrey W. Elias, PhD
Arch Neurol. 1988;45(8):861-864.
Abstract
| |
• Controlled-release carbidopa levodopa 50/200 (SINEMET CR) and standard carbidopa/levodopa (SINEMET 25/100) were compared in a double-blind, six-month, crossover study involving 21 patients with chronic Parkinson's disease and motor response fluctuations. Daily dosage frequency was significantly reduced with SINEMET CR compared with SINEMET 25/100, while the daily amount of levodopa required with SINEMET CR was significantly greater. No significant differences in disability ratings, motor response fluctuations, or safety were detected during double-blind conditions. In the open-label, dose-finding phase of the study, SINEMET CR was superior to standard SINEMET 25/100 in patient ratings of percent "on" time (good motor function), clinical assessments of motor function, and activities of daily living. This finding resulted from a depreciation of the value of the "old drug" rather than an overestimation of the value of the experimental drug. This double-blind study also suggested that elderly male patients with Parkinson's disease derived the greatest benefit from SINEMET CR.
Author Affiliations
From the Departments of Medical and Surgical Neurology (Drs Hutton and Román and Ms Imke) and Psychology (Dr Elias), Texas Tech University Health Sciences Center, Lubbock; and Lubbock (Tex) Veterans Administration Outpatient Clinic (Dr Hutton and Mr Morris).
Footnotes
Accepted for publication April 4, 1988.
Reprint requests to Department of Medical and Surgical Neurology, Texas Tech University Health Sciences Center, Lubbock, TX 79430 (Dr Hutton).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Pahwa et al.
Neurology 2006;66:983-995.
ABSTRACT
| FULL TEXT
Therapy of Patients With Parkinson's Disease
Paulson
Arch Neurol 1994;51:754-756.
ABSTRACT
Standard and Controlled-Release Levodopa/Carbidopa in Patients With Fluctuating Parkinson's Disease on a Protein Redistribution Diet: A Preliminary Report
Karstaedt et al.
Arch Neurol 1991;48:402-405.
ABSTRACT
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Pahwa et al.
Neurology 2006;66:983-995.
ABSTRACT
| FULL TEXT
|
